NCT02433652View on ClinicalTrials.gov

Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

November 30, 2016

Conditions
Dengue
Interventions
BIOLOGICAL

Recombinant live attenuated trivalent dengue vaccine

Contains 10\^3.3 plaque forming units (PFU)/mL of rDEN1Δ30, 10\^3.3 PFU/mL of rDEN3Δ30/31-7164 and 10\^3.3 PFU/mL of rDEN4Δ30. It is administered in 0.5 mL containing 10\^3.0 PFU of each component.

BIOLOGICAL

Placebo

BIOLOGICAL

rDEN2Δ30-7169 vaccine

Live recombinant attenuated DENV-2 candidate vaccine virus; will be administered at a dose of 10\^3 PFU

Trial Locations (2)

21205

Center for Immunization Research (CIR), Johns Hopkins School of Public Health, Baltimore

05405

University of Vermont, Burlington

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02433652 - Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2 | Biotech Hunter | Biotech Hunter